Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant salmonella enterica

Journal of Clinical Microbiology

Volumn 53, Issue 11, 2015, Pages 3411-3417

  Skov, Robert ^a   Matuschek, Erika ^b   Sjolund Karlsson, Maria ^c   Ahman, Jenny ^b   Petersen, Andreas ^a   Stegger, Marc ^a   Torpdahl, Mia ^a   Kahlmeter, Gunnar ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b EUCAST Development Laboratory   (Sweden)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ENOXACIN; ENROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV;

AAC(6') IB CR GENE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; DRUG SCREENING; GENE MUTATION; GENETIC VARIABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; QEPA GENE; QNRA GENE; QNRB GENE; QNRD GENE; QNRS GENE; SALMONELLA ENTERICA; BACTEREMIA; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PROCEDURES; SALMONELLA INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BASE SEQUENCE; CIPROFLOXACIN; DISK DIFFUSION ANTIMICROBIAL TESTS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LEVOFLOXACIN; NALIDIXIC ACID; OFLOXACIN; PEFLOXACIN; SALMONELLA ENTERICA; SALMONELLA INFECTIONS; SEQUENCE ANALYSIS, DNA;

EID: 84945176706     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01287-15     Document Type: Article

References (32)

1. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A, Hoekstra RM. 2010. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 50:882-889. http://dx.doi.org/10.1086/650733.
2. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. 2003. Reevaluating fluo-roquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 37:75-81. http://dx.doi.org/10.1086/375602.
3. Sjolund-Karlsson M, Folster JP, Pecic G, Joyce K, Medalla F, Rickert R, Whichard JM. 2009. Emergence of plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates from humans in the United States. Antimicrob Agents Chemother 53:2142-2144. http://dx.doi.org/10.1128/AAC.01288-08.
4. Stevenson JE, Gay K, Barrett TJ, Medalla F, Chiller TM, Angulo FJ. 2007. Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob Agents Chemother 51:195-197. http://dx.doi.org/10.1128/AAC.00222-06.
5. Threlfall EJ, Skinner JA, Ward LR. 2001. Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A. J Antimicrob Chemother 48:740-741. http://dx.doi.org/10.1093/jac/48.5.740.
6. Hooper DC. 2003. Mechanisms of quinolone resistance, p 41-67. In Hooper DC, Rubinstein E (ed), Quinolone antimicrobial agents, 3rd ed. ASM Press, Washington, DC.
7. Parry CM, Threlfall EJ. 2008. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 21:531-538. http://dx.doi.org/10.1097/QCO.0b013e32830f453a.
8. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. 2009. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22:664-689. http://dx.doi.org/10.1128/CMR.00016-09.
9. Helms M, Vastrup P, Gerner-Smidt P, Mølbak K. 2002. Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg Infect Dis 8:490-495. http://dx.doi.org/10.3201/eid0805.010267.
10. Humphries RM, Fang FC, Aarestrup FM, Hindler JA. 2012. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 55:1107-1113. http://dx.doi.org/10.1093/cid/cis600.
11. Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, Diep TS, Day NP, Solomon T, White NJ, Piddock LJ, Parry CM. 1997. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 25:1404-1410. http://dx.doi.org/10.1086/516128.
12. European Committee on Antimicrobial Susceptibility Testing. 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 4.0, 2014. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-4.0.pdf.
13. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Cavaco LM, Aarestrup FM. 2009. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanismsqnrA, qnrB, qnrS, andaac(6=)Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions. J Clin Microbiol 47:2751-2758. http://dx.doi.org/10.1128/JCM.00456-09.
16. Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P. 1999. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 37: 3572-3577.
17. Skov R, Torpdahl M, Stegger M, Frimodt-Møller N. 2010. Cipro-floxacin 1g disk diffusion for detection of ciprofloxacin resistance in Salmonella spp, abstr D-754. Abstr 50th Intersci Conf Antimicrob Agents Chemother.
18. Randall LP, Coldham NG, Woodward MJ. 2005. Detection of mutations in Salmonella enterica gyrA, gyrB, parC and parE genes by denaturing high performance liquid chromatography (DHPLC) using standard HPLC instrumentation. J Antimicrob Chemother 56:619-623. http://dx.doi.org/10.1093/jac/dki293.
19. Ahmed AM, Miyoshi S, Shinoda S, Shimamoto T. 2005. Molecular characterization of a multidrug-resistant strain of enteroinvasive Esche-richia coli O164 isolated in Japan. J Med Microbiol 54:273-278. http://dx.doi.org/10.1099/jmm.0.45908-0.
20. Cavaco LM, Frimodt-Moller N, Hasman H, Guardabassi L, Nielsen L, Aarestrup FM. 2008. Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinolone-resistant Escherichia coli isolated from humans and swine in Denmark. Microb Drug Resist 14:163-169. http://dx.doi.org/10.1089/mdr.2008.0821.
21. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. 2007. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother 60: 394-397. http://dx.doi.org/10.1093/jac/dkm204.
22. Cavaco LM, Hasman H, Xia S, Aarestrup FM. 2009. qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. An-timicrob Agents Chemother 53:603-608. http://dx.doi.org/10.1128/AAC.00997-08.
23. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. 2006. Prevalence in the United States of aac(6=)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 50:3953-3955. http://dx.doi.org/10.1128/AAC.00915-06.
24. Perichon B, Courvalin P, Galimand M. 2007. Transferable resistance to aminoglycosides bymethylationof G1405in 16S rRNA andtohydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimi-crob Agents Chemother 51:2464-2469. http://dx.doi.org/10.1128/AAC.00143-07.
25. International Organization for Standardization. 2006. Clinical laboratory testing and in vitro diagnostic test systems-susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776-1:2006. International Organization for Standardization, Geneva, Switzerland.
26. European Committee on Antimicrobial Susceptibility Testing. 2012. EU-CAST disk diffusion test manual for antimicrobial susceptibility testing, version 2.0. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/Disk-method-description-v-2.0.pdf.
27. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial disk susceptibility tests; approved standard-11th ed. CLSI document M02-A11. Clinical and Laboratory Standards Institute, Wayne, PA.
28. WHO Expert Committee on Biological Standardization. 1977. WHO Expert Committee on Biological Standardization: twenty-eighth report. World Health Organ Tech Rep Ser 1977:1-133.
29. European Committee on Antimicrobial Susceptibility Testing. 2012. EUCAST recommended strains for internal quality control, version 2.0, 2012. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/EUCAST-QC-tables-2.0.pdf.
30. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12:83-88. http://dx.doi.org/10.1038/nm1347.
31. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
32. European Committee on Antimicrobial Susceptibility Testing. 2015. Routine and extended internal quality control as recommended by EUCAST, version 5.0, 2015. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/QC/EUCAST-QC-tables-5.0-routine-and-extended.pdf.